• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acadia Pharmaceutica (NQ: ACAD )

    18.00 -0.35 (-1.91%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,796,482
    Open 18.47
    Bid (Size) 17.72 (15)
    Ask (Size) 18.90 (4)
    Prev. Close 18.35
    Today's Range 17.71 - 18.49
    52wk Range 14.55 - 33.99
    Shares Outstanding 162,625,379
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals
    Via Benzinga

    Performance

    YTD
    -41.67%
    -41.67%
    1 Month
    +21.29%
    +21.29%
    3 Month
    +4.71%
    +4.71%
    6 Month
    -35.67%
    -35.67%
    1 Year
    -45.44%
    -45.44%

    More News

    Read More
    This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Expert Ratings For ACADIA Pharmaceuticals
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
    Via Benzinga
    Expert Ratings For ACADIA Pharmaceuticals
    Via Benzinga
    Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
    From Acadia Pharmaceuticals, Inc.
    Via Business Wire
    3 Sorry Pharma Stocks to Sell in May While You Still Can
    Via InvestorPlace
    After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
    Via Benzinga
    Topics Data Breach
    Exposures Information Security
    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar
    Via InvestorPlace
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
    Via Benzinga
    Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    3 Pharma Stocks to Sell in April Before They Crash & Burn
    Via InvestorPlace
    Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.